See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

ReliOn at Wal-Mart

Bob Guest

ReliOn at Wal-Mart

First Look:  New iPhone App for Logging Readings and Much More

Hadi El Heneidi - Agamatrix

First Look: New iPhone App for Logging Readings and Much More

Injections

Updated 95 weeks ago
Lilly Says Its New Injectible Outperforms 3 Popular Diabetes Drugs
Nov 5, 2012 | 
Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.
Spreading Diabetes Awareness Isn’t as Easy as It Looks
Oct 18, 2012 | 
You might not realize this, but I'm actually pretty shy. I often find myself wishing that I had my husband's confidence. He doesn't worry about drawing attention to himself at parties or work. He embraces the mindset that if you don't like him, it's your problem, not his, and he shows himself to everyone just as he is.
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

ReliOn at Wal-Mart

Bob Guest

ReliOn at Wal-Mart

The i-port®

Davida Kruger and KK Patton

The i-port®

First Look:  New iPhone App for Logging Readings and Much More

Hadi El Heneidi - Agamatrix

First Look: New iPhone App for Logging Readings and Much More

FDA Gives Long-Awaited Nod to Amylin’s Bydureon
Feb 3, 2012 | 
After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year.
“Grip, Rip, and Sip”
Jan 16, 2012 | 
Ethan Lewis, diagnosed with type 1 diabetes at the age of 12, founded GlucoBrands only 11 years later. The company produces a portable, inexpensive, tasty, fast-acting glucose gel that people can take to quickly restore healthy blood sugar levels when they experience hypoglycemia.
There’s No Shame in Taking Insulin Injections in Public
Jan 12, 2012 | 
Recently, there has been a great deal of discussion on the subject of testing your blood sugar and taking insulin shots in public. A shocking number of people on social networks have commented that their family members don't want them to test their blood sugar or take their shots in public. They report having to inject in restrooms or even through their clothing to avoid drawing attention or offending their families. One hypersensitive husband even objected when his recently diagnosed wife took a shot in the relative privacy of their car.
 
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.